Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

被引：0
|
作者：
Ghader Mohammadnezhad
Behniya Azadmehr
Mehdi Mirheidari
Nazila Yousefi
机构：
[1] Shahid Beheshti University of Medical Sciences,Student Research Committee, School of Pharmacy
[2] Shahid Beheshti University of Medical Sciences,Department of Pharmacoeconomics and Pharma Management, School of Pharmacy
来源：
Cost Effectiveness and Resource Allocation | / 20卷
关键词：
Dapagliflozin; SGLT-2 inhibitors; Economic evaluation; Cost-effectiveness analysis; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [2] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [3] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [4] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [5] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [6] COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS
    Cavusoglu, Y.
    Demir, O.
    Dinc, M.
    Ozsoy, A.
    Erdogan, A.
    Ozer, S.
    VALUE IN HEALTH, 2022, 25 (01) : S66 - S66
  • [7] COST-OFFSET ANALYSIS OF DAPAGLIFLOZIN IN TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) IN CHINA
    Guan, H.
    Liu, Y.
    Feng, Y.
    He, Y.
    Liu, J.
    VALUE IN HEALTH, 2021, 24 : S73 - S73
  • [8] Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review
    Rezapour, Aziz
    Tashakori-Miyanroudi, Mahsa
    Haghjoo, Majid
    Barzegar, Mohammad
    Tatarpour, Parvin
    Souresrafil, Aghdas
    Gorji, Hassan Abolghasem
    Yousefzadeh, Negar
    Sheikhy-Chaman, Mohammadreza
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (02) : 127 - 144
  • [9] Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review
    Aziz Rezapour
    Mahsa Tashakori-Miyanroudi
    Majid Haghjoo
    Mohammad Barzegar
    Parvin Tatarpour
    Aghdas Souresrafil
    Hassan Abolghasem Gorji
    Negar Yousefzadeh
    Mohammadreza Sheikhy-Chaman
    American Journal of Cardiovascular Drugs, 2023, 23 : 127 - 144
  • [10] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
12345